Printer Friendly

Sigma-Aldrich licenses DNA regulation technology for $13 million.

St. Louis, MS and Richmond, CA 7/10/07--Sigma-Aldrich has licensed Sangamo BioSciences' zinc finder DNA-binding proteins (ZFPs) for development of research reagents for the regulation of gene expression in living cells. Sigma-Aldrich also acquired rights to sublicense the technology for research applications. Sigma-Aldrich will initially pay Sangamo $13.75 million in the form of an upfront licensing payment and purchase of one million shares of Sangamo stock for $7.75 per share. Additional payments will be made to Sangamo, which is eligible to receive up to $22 million, depending on milestones. In addition, Sangamo will receive royalty payments and 50% of sublicensing revenues in the first two years and 25% thereafter. "We believe that Sangamo's ZFP technology could fundamentally alter the way in which research on living cells and organisms is conducted. By vastly improving the precision and efficiency with which genomes of living organisms can be modified and regulated, ZFPs provide significant potential for both research and development," stated Sigma-Aldrich President and CEO Jai Nagarkatti.

According to Sangamo, if all milestones are achieved, the company could be eligible to receive $60 million in payments. ZFPs have the ability to add, delete, activate, correct and repress a target gene. Among the possible research applications of ZFPs are the generation of panels of cell lines for use in drug screening and the creation of cellular models of disease and transgenic animals. As part of the agreement, Sigma-Aldrich and Sangamo will undertake a three-year research collaboration.
COPYRIGHT 2007 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Executive Briefing: News & Views for Executives
Publication:Instrument Business Outlook
Date:Jul 15, 2007
Words:245
Previous Article:Mettler-Toledo sells SFC business.
Next Article:Thermo Fisher Scientific buys cell culture technology.
Topics:


Related Articles
Sigma-Aldrich acquires Oligo Maker Proligo.
Sigma-Aldrich to acquire Proligo group to strengthen genomics research tools portfolio.
Sigma-Aldrich files suit for infringement of RNAi patents.
Sigma-Aldrich and Oxford BioMedica pursue protection of RNAi-related intellectual property; file suit against Open Biosystems.
Sigma-Aldrich adds to service offerings.
Sigma-Aldrich grants Pfizer non-exclusive worldwide license to use ddRNAi in research programs.
Sigma-Aldrich and Oxford BioMedica win key ruling in open biosystems patent Infringement dispute.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters